Skip to main content

MMP14 KO cell line available to order. KO validated by Immunocytochemistry, Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 10 bp deletion Frameshift = 99.9%.

Be the first to review this product! Submit a review

Images

Western blot - Human MMP14 knockout A-431 cell line (AB261890), expandable thumbnail
  • Next Generation Sequencing - Human MMP14 knockout A-431 cell line (AB261890), expandable thumbnail
  • Next Generation Sequencing - Human MMP14 knockout A-431 cell line (AB261890), expandable thumbnail
  • Immunocytochemistry/ Immunofluorescence - Human MMP14 knockout A-431 cell line (AB261890), expandable thumbnail

Key facts

Cell type
A-431
Species or organism
Human
Tissue
Skin
Form
Liquid
Knockout validation
Immunocytochemistry, Next Generation Sequencing, Western blot
Mutation description
Knockout achieved by CRISPR/Cas9 X = 10 bp deletion Frameshift = 99.9%

Alternative names

MMP-X1, MMP14_HUMAN, MT-MMP 1, MT1-MMP, Matrix metallopeptidase 14 (membrane inserted), Matrix metalloproteinase-14, Membrane type 1 metalloprotease, Membrane-type matrix metalloproteinase 1, Membrane-type-1 matrix metalloproteinase

Recommended products

MMP14 KO cell line available to order. KO validated by Immunocytochemistry, Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 10 bp deletion Frameshift = 99.9%.

Key facts

Cell type
A-431
Form
Liquid
Mutation description
Knockout achieved by CRISPR/Cas9 X = 10 bp deletion Frameshift = 99.9%
Disease
Epidermoid Carcinoma
Concentration
Loading...

Properties

Gene name
MMP14
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Immunocytochemistry, Next Generation Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type A-431 cell line (ab263975). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Matrix metalloproteinase 14 (MMP14) also known as MT1-MMP is a membrane-bound enzyme involved in the breakdown of the extracellular matrix. This protease has a molecular weight of approximately 66 kDa and consists of various structural domains including a catalytic domain and a hinge region. MMP14 is expressed in many tissues including the stromal and cancer cells where it facilitates cell migration and tissue remodeling.

Biological function summary

MMP14 influences extracellular matrix degradation enabling cellular invasion and migration. It exists as a part of macromolecular complexes at the cell surface interacting with other metalloproteinases. This interaction assists in the activation of other MMPs such as pro-MMP2 which further amplify matrix remodeling activities. The hinge region of MMP14 lends flexibility allowing it to effectively engage with substrate proteins.

Pathways

MMP14 significantly affects cell signaling and tissue remodeling pathways. One critical pathway involves the activation of pro-MMP2 which is dependent on MMP14's proteolytic activity. MMP14 also plays a role in the regulation of cell proliferation and apoptosis through its interaction with proteins such as TIMP-2. This relationship between MMP14 and other regulatory proteins emphasizes its functional integration within major biological networks.

Associated diseases and disorders

High MMP14 levels correlate strongly with cancer progression especially in cancers such as breast cancer and melanoma. The ability of MMP14 to degrade the extracellular matrix facilitates tumor invasion and metastasis. Through its regulatory activities MMP14 connects with other proteins like VEGF influencing angiogenesis within tumor microenvironments. Additionally MMP14 involvement in arthritic conditions highlights its role in joint degradation processes worsening the disease through augmented cartilage breakdown.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com